IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Argenx's Sjögren’s trial failure caused Immunovant (IMVT) and Roivant (ROIV) stocks to slide, raising concerns about their similar studies. Wainwright maintained a 'Buy' rating on Argenx (ARGX) with a $1,202 price target. Retail sentiment shifted from bearish to bullish for ARGX, while IMVT and ROIV saw neutral and bearish sentiment, respectively. Year-to-date, IMVT is up 19%, ROIV up 55%, and ARGX down 4%.
How this was made
The 30-second read
Why it matters
The key actionable element is the analyst’s stance shift for IMVT (more cautious) versus maintained bullishness for ARGX (Buy and $1,202 target), which can drive relative performance within the drug-class complex.
Market read
Traders may rebalance biotech exposure based on drug-class trial failure read-through, while ARGX may be treated as comparatively supported by the reiterated Buy.
What to watch
The excerpt lacks details on which endpoints failed, whether the failure is mechanism-specific, and whether IMVT-1402 is directly comparable to the failed program, so read-across may be overstated.
Background
The piece frames a “surprising setback” from Argenx Sjögren’s trial failure and discusses how that affects analyst caution on Immunovant’s IMVT-1402 mid-stage study.
Ticker impact
Article says IMVT-1402 Sjögren’s mid-stage study faced a “surprising setback,” prompting Wainwright to be more cautious on implications for the program.
Likely downside pressure as traders reprice probability of success for the Sjögren’s mid-stage program.
The text links the trial failure to increased caution about what it implies for IMVT-1402, which typically weighs on biotech risk assets even without new quantitative endpoints.
Headline indicates ROIV shares slide alongside IMVT on the same drug-class trial failure narrative, implying read-across risk to Roivant’s related exposure.
Likely continued selling pressure tied to class-level skepticism rather than company-specific new data.
The provided body does not specify ROIV’s direct trial or asset; it mainly discusses IMVT-1402 and Argenx, so ROIV’s linkage is inferred from the headline framing.
Article states Wainwright kept a “Buy” on Argenx and reiterated a $1,202 price target despite the trial setback affecting the drug class.
Potential relative outperformance versus IMVT/ROIV as the analyst maintains a Buy and high target.
The body explicitly says Wainwright kept Buy and a $1,202 target on ARGX, which can counterbalance broad drug-class risk.
Market effects
Reinforces biotech drug-class binary risk, likely increasing caution and widening perceived probability-of-failure for similar immunology assets.
Primarily US-listed biotech sentiment spillover; no specific regional macro catalyst mentioned.
Limited global relevance beyond immunology/biotech risk appetite, since the article focuses on trial read-through and analyst positioning.
Counterpoint
The maintained ARGX Buy and target suggest the market may be over-discounting class-level implications; traders could favor relative value rather than broad de-risking.
Key entities
- companyImmunovant
Discussed via its IMVT-1402 Sjögren’s mid-stage study and analyst caution after the trial setback.
- companyRoivant Sciences
Included in the headline as sliding alongside IMVT on drug-class trial failure read-through.
- companyArgenx
Wainwright kept a Buy and $1,202 price target despite the drug-class setback.
